Table 2.

Tumor and patient characteristics of the analyzed samples

n = 1049	Prosigna® molecular subtype
	Luminal A		Luminal B		HER2-enriched		Basal-like
	n = 679	%	n = 350	%	n = 8	%	n = 12	%
Age at diagnosis (years)
< 50	211	31	74	21	3	38	5	42
> 50	459	68	271	77	5	63	7	58
Na	9	1	5	1	0	0	0	0
Tumor type
Ductal	522	77	293	83	7	88	11	92
Lobular	110	16	29	8	0	0	0	0
Others	31	5	19	5	0	0	1	8
Na	16	2	9	3	1	13	0	0
Tumor size (mm)
≤ 20	536	79	234	67	6	75	10	83
> 20	143	21	116	33	2	25	2	17
ER
Positive	676	100	350	100	8	100	8	67
Negative	1	0	0	0	0	0	4	33
Na	2	0	0	0	0	0	0	0
PR
Positive	611	90	324	92	5	63	8	67
Negative	66	10	26	7	3	38	4	33
Na	2	0	0	0	0	0	0	0
Ki67 index (%)
< 14	399	59	69	20	0	0	0	0
14–20	189	28	119	34	1	13	0	0
> 20	91	13	162	46	7	88	12	100
Ki67 index (%)
< 13	392	58	64	18	0	0	0	0
> 13	287	42	286	81	8	100	12	100
Histological grade
1	81	12	12	3	0	0	0	0
2	379	56	177	50	1	13	2	17
3	25	4	53	15	2	25	6	50
Na	194	29	109	31	5	63	4	33
Prosigna ROR
Low	461	68	1	0	0	0	1	8
Intermediate	194	29	145	41	1	13	9	75
High	24	4	204	58	7	88	2	17
Lymph nodes
0	521	77	286	82	7	88	10	83
1–3	158	23	64	18	1	13	2	17

NA non-available, ER estrogen receptor, PR progesterone receptor, HER human epidermal growth factor receptor 2, ROR risk of recurrence